Wegovy (semaglutide) injection 1.7 mg or 2.4 mg and Wegovy (semaglutide) tablets 25 mg are prescription medicines used with a reduced calorie diet and increased physical activity to: reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight
In early 2025, the journal Cureus posted a case study of a 57-year-old individual who started taking tirzepatide
This is considered the ideal diet that will result in the maximum weight loss effect, which can be up to 20% change in body weight after two years
The FLOW trial showed a 24% reduction in major kidney events in people with type 2 diabetes and CKD, and the SMART trial showed a 52% reduction in urinary albumin leakage, a key marker of kidney damage
Half-life and washout data
But they are only one piece of a much larger care model